Madrigal Pharmaceuticals (MDGL) Share-based Compensation (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Share-based Compensation data on file, last reported at $34.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $34.0 million, up 62.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.2 million (up 37.46% YoY), and the FY2025 annual result was $98.1 million, up 22.85% from the prior year.
• Share-based Compensation improved to $34.0 million in Q1 2026 per MDGL's latest filing, from $25.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $34.0 million in Q1 2026 and troughed at $7.5 million in Q1 2022.
• A 5-year average of $17.3 million and a median of $17.7 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation dropped 2.87% in 2022, then jumped 122.4% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $8.1 million in 2022, then soared by 83.77% to $14.9 million in 2023, then climbed by 19.01% to $17.7 million in 2024, then surged by 45.89% to $25.8 million in 2025, then soared by 31.91% to $34.0 million in 2026.
• Business Quant data shows MDGL's Share-based Compensation at $34.0 million in Q1 2026, $25.8 million in Q4 2025, and $26.3 million in Q3 2025.